Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

Alpha Cognition, a biopharmaceutical firm dedicated to treating neurodegenerative diseases, has named Dr. Robert Wills as its new Chairman, replacing Len Mertz who retired. This strategic shift comes as the company aims to bolster its leadership in the development of innovative therapies. Dr. Wills' extensive background in the life sciences sector could bring fresh insights and drive the company's mission forward. This leadership change underscores Alpha Cognition's commitment to advancing its research and potentially shaping the future of neurodegenerative disease treatment.